Jupiplatin 50 Injection contains Oxaliplatin at a concentration of 2 mg/ml and is indicated for the treatment of colorectal cancer, including adjuvant therapy for stage III colon cancer and metastatic disease. Oxaliplatin is a platinum-based chemotherapeutic agent that exerts its cytotoxic effect by forming platinum-DNA adducts, leading to inhibition of DNA synthesis and transcription, ultimately inducing apoptosis in rapidly dividing cancer cells. Jupiplatin 50 is administered intravenously, typically in combination with fluoropyrimidine-based chemotherapy regimens such as 5-fluorouracil and leucovorin. The dosing schedule and duration depend on the specific treatment protocol and patient tolerance. Common adverse effects include peripheral neuropathy, myelosuppression, gastrointestinal disturbances such as nausea, vomiting, diarrhea, and mucositis. Hypersensitivity reactions may occur and require prompt management. Renal and hepatic function should be monitored throughout treatment due to potential toxicity. Jupiplatin 50 Injection should be used with caution in patients with preexisting neuropathy or impaired organ function. It is contraindicated in patients with known hypersensitivity to platinum compounds. Proper administration and adherence to recommended dosing guidelines are essential to maximize therapeutic efficacy and minimize adverse effects.